A pancreatic cancer expert on why Revolution Medicines’ study could ‘open up a new era’ of treatment statnews.comRevolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial CNBCThis Pill May Help Pancreatic Cancer Patients Live Longer Forbes
From Benign Growth to Pancreatic Cancer: New Study Shows How the Switch Gets Flipped Memorial Sloan Kettering Cancer Center
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting Yahoo Finance
Beloved Radio Host Retires After 48 Years. A Few Months Later, He's Diagnosed with Late-Stage Pancreatic Cancer People.com
Lustgarten Foundation '26 NYC Walk for Pancreatic Cancer Research on April 19 CBS News
Pivotal pancreatic cancer data power Revolution to massively upsized $2B offering FirstWord Pharma
Hamden firefighters rally around member whose wife was recently diagnosed with pancreatic cancer New Haven Register
Good News in Pancreatic Cancer; Breast Screening Debate; AI May Erode Docs' Skills MedPage Today
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” The Cancer Letter
Vermilion Parish woman shares pancreatic cancer battle online KLFY.com
First RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma: What You Need to Know Pancreatic Cancer Action Network
Two New Drugs Offer Hope for Pancreatic Cancer Time Magazine
New Drug Doubles One-Year Survival in Pancreatic Cancer Trial Northwestern University
New pancreatic cancer drug Elraglusib, created at Northwestern Medicine, helps patients live longer: Dr. Deva Mahalingam ABC7 Chicago
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial Nature
Daraxonrasib Yields Significant Survival Advantages vs Chemotherapy in Metastatic Pancreatic Cancer OncLive
New targeted therapy gives hope to pancreatic cancer patients and families WGN-TV
Daraxonrasib Shows Significant OS Benefit in Metastatic Pancreatic Cancer Targeted Oncology
Central Ohio advocates join national movement to end pancreatic cancer 10TV
Revolution Medicines touts ‘unprecedented’ data for pancreatic cancer pill statnews.com
OncLive Weekly News Quiz (4/17/2026): Did You See This Week's Updates in CLL, Pancreatic Cancer, and More? OncLive
PanCAN Statement on Positive Overall Survival Results from Revolution Medicines Phase III Trial Pancreatic Cancer Action Network
For Ben Sasse, Revolution Medicines’ pancreatic cancer trial felt like his best, only option statnews.com
A Q&A with Streamer & Strider Thad Bargman Pancreatic Cancer Action Network
Patient-Centered Approaches Are Vital for Navigating Treatment Decisions in Pancreatic Cancer OncLive
Pivotal Phase III Pancreatic Cancer Trial Advances RAS-Targeting Daraxonrasib Inside Precision Medicine
Revolution rises 40% as pancreatic cancer drug doubles survival BioSpace
Targeted agent offers ‘unprecedented’ survival benefit in metastatic pancreatic cancer Healio
Emerging Strategies to Overcome Resistance in Pancreatic Cancer Targeted Oncology
Epigenetic Target Could Sensitize Pancreatic Cancer to Immunotherapy Inside Precision Medicine
Elraglusib Delivers Rare Survival Benefit in Pancreatic Cancer Inside Precision Medicine
Finally, Real Progress Against Pancreatic Cancer Bloomberg.com
Revolution doubles stock offering target to $2B following pancreatic cancer win BioSpace
Elraglusib Combo Doubles Survival in Pancreatic Cancer Cure Today
More Evidence Links Physical Activity With Improved Cancer Survival Cancer Health
Wungki Park: POLAR Study Provides Rationale for Precision Immunotherapy in Pancreatic Cancer Oncodaily
Combination therapy doubles one-year survival in pancreatic cancer trial Drug Discovery News
Theriva to present VCN-01 pancreatic cancer trial data at AACR Investing.com
Pancreatic cancer drug doubles median survival time Semafor
New Pancreatic Cancer Drug Nearly Doubles Survival. Here’s What Patients Should Know Forbes